Asia-Pacific Pulmonary Function Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Pulmonary Function Testing Market Size

• The Asia-Pacific pulmonary function testing market size was valued at USD 776.90 million in 2024 and is expected to reach USD 1,406.34 million by 2032, at a CAGR of 7.70% during the forecast period
• The market growth is largely driven by the increasing prevalence of chronic respiratory diseases such as COPD and asthma, coupled with the growing elderly population across countries such as China, India, and Japan, which are more susceptible to pulmonary disorders
• Furthermore, rising healthcare expenditure, expanding diagnostic infrastructure, and the growing emphasis on early disease detection are encouraging the adoption of pulmonary function testing in hospitals and diagnostic labs. These dynamics are collectively fueling the demand for advanced respiratory monitoring tools, thereby significantly enhancing the region’s market growth

Asia-Pacific Pulmonary Function Testing Market Analysis

• Pulmonary function testing, which encompasses hardware, software, and services for assessing lung performance, is becoming a critical component of diagnostic protocols across Asia-Pacific, especially in both hospital and outpatient settings, due to increasing respiratory disease prevalence and expanding healthcare access
• The escalating demand for pulmonary function testing is primarily fueled by rising air pollution levels, growing geriatric population, and increasing awareness regarding early detection of obstructive and restrictive lung disorders
• China dominated the Asia-Pacific pulmonary function testing market with the largest revenue share of 39.3% in 2024, supported by large-scale investments in healthcare infrastructure, high incidence of respiratory diseases, and a strong public health focus on chronic disease screening
• India is expected to be the fastest-growing country in the Asia-Pacific pulmonary function testing market during the forecast period due to rising urbanization, expanding diagnostics penetration, and increasing government focus on non-communicable diseases
• Hardware segment dominated the Asia-Pacific pulmonary function testing market with a market share of 65.7% in 2024, driven by widespread adoption of spirometers, plethysmographs, and gas analyzers in hospitals and diagnostic laboratories across major Asia-Pacific economies

Report Scope and Asia-Pacific Pulmonary Function Testing Market Segmentation   

Asia-Pacific Pulmonary Function Testing Market Trends

Technological Advancement and Home-Based Testing Expansion

• A notable and accelerating trend in the Asia-Pacific pulmonary function testing market is the rapid adoption of technologically advanced diagnostic systems and the increasing availability of portable devices that support home-based respiratory assessments. These developments are significantly improving accessibility and early detection of pulmonary diseases, especially in rural and aging populations
  • For instance, companies such as NDD Medical Technologies and Vitalograph are introducing compact spirometry devices that connect to smartphones or tablets, enabling healthcare providers to conduct accurate testing even in non-clinical settings. Such tools are proving invaluable in community health programs and telemedicine initiatives across India, China, and Southeast Asia
• Advanced PFT systems now integrate digital interfaces and real-time data sharing capabilities, supporting electronic medical record (EMR) integration and cloud storage, which enhances efficiency in diagnostics and longitudinal disease tracking
• In addition, the integration of artificial intelligence in pulmonary testing is emerging, with smart algorithms being used to interpret test results, reduce technician dependency, and minimize human error especially beneficial in low-resource settings
• These innovations are fueling a shift from centralized hospital testing to decentralized and preventive care models, particularly driven by growing government initiatives targeting early diagnosis of chronic respiratory diseases
• The convergence of portable technology, AI-enabled analysis, and remote connectivity is redefining how pulmonary diagnostics are accessed and delivered in Asia-Pacific, offering new avenues for patient engagement and improving outcomes in both urban and underserved populations

Asia-Pacific Pulmonary Function Testing Market Dynamics

Driver

High Respiratory Disease Burden Coupled with Expanding Healthcare Access

• The increasing prevalence of respiratory illnesses driven by high levels of pollution, smoking, and aging populations remains a major driver for the pulmonary function testing market in Asia-Pacific. Rising awareness of chronic respiratory diseases such as COPD and asthma has led to increased demand for early and accurate diagnosis using pulmonary testing tools
  • For instance, China’s Healthy China 2030 initiative emphasizes the reduction of chronic diseases, including lung-related illnesses, through early screening, which directly supports the growth of pulmonary testing services
• In addition, countries such as India are investing in primary care infrastructure and mobile health programs that include pulmonary function screening, especially in high-risk populations
• Growing healthcare expenditure, coupled with increasing adoption of advanced diagnostic technologies by hospitals and clinics, is further accelerating market penetration, especially in urban and semi-urban areas
• Moreover, increased patient awareness, government-led screening initiatives, and improved insurance coverage are making pulmonary function tests more accessible, contributing to consistent market expansion across the region

Restraint/Challenge

Lack of Skilled Technicians and Standardized Testing Protocols

• One of the key challenges in the Asia-Pacific pulmonary function testing market is the shortage of trained personnel capable of administering and interpreting tests such as spirometry and body plethysmography with precision. This is particularly evident in rural healthcare centers and smaller diagnostic facilities, where inconsistent testing practices may lead to misdiagnosis or inaccurate assessments
  • For instance, despite increasing deployment of PFT devices in community health programs, inadequate technician training often results in unreliable data, undermining trust in diagnostics
• In addition, lack of standardization in testing protocols and variations in equipment calibration across healthcare settings limit interoperability and data consistency, particularly when patients transition between providers
• Addressing these challenges requires focused investment in healthcare training programs, certification standards, and the adoption of user-friendly, automated systems that reduce operator dependency
• Collaborative efforts between governments, health institutions, and device manufacturers to build skilled capacity and promote best practices will be crucial to fully realizing the potential of pulmonary function testing across the Asia-Pacific region

Asia-Pacific Pulmonary Function Testing Market Scope

The market is segmented on the basis of type, patient type, application, and end user.

• By Type

On the basis of type, the pulmonary function testing market is segmented into hardware, services, and software. The hardware segment dominated the market with the largest revenue share of 65.7% in 2024, primarily due to the widespread use of spirometers, body plethysmographs, and diffusion capacity machines in clinical settings. Hospitals and diagnostic laboratories across Asia-Pacific are increasingly investing in advanced testing equipment to address the growing burden of chronic respiratory diseases. The demand is further supported by improved availability of compact and portable diagnostic hardware suitable for both urban and rural healthcare setups.

The software segment is anticipated to witness the fastest growth rate of 18.4% from 2025 to 2032, driven by the increasing integration of digital platforms with testing devices. The rise of AI-powered data analytics, cloud-based storage, and telehealth compatibility is boosting demand for pulmonary diagnostic software that enables real-time reporting, remote monitoring, and EMR integration.

• By Patient Type

On the basis of patient type, the pulmonary function testing market is segmented into pediatric, adult, and geriatric populations. The adult segment held the largest market revenue share of 56.7% in 2024, attributed to the high prevalence of smoking, urban pollution, and occupational exposure to respiratory irritants across the working-age population. Adults often undergo pulmonary testing for early detection and monitoring of asthma, COPD, and lung function decline due to environmental factors.

The geriatric segment is expected to grow at the fastest CAGR of 17.1% from 2025 to 2032, as age-related lung function deterioration and a higher incidence of chronic respiratory diseases such as pulmonary fibrosis and emphysema drive greater demand for routine lung health assessments in this demographic.

• By Application

On the basis of application, the pulmonary function testing market is segmented into obstructive lung disease and restrictive lung disease. The obstructive lung disease segment dominated the market with a revenue share of 60.4% in 2024, driven by the high prevalence of conditions such as asthma and chronic obstructive pulmonary disease (COPD) in major countries including China and India. The increasing focus on disease monitoring and outpatient management programs is further strengthening demand in this category.

The restrictive lung disease segment is expected to grow steadily over the forecast period, fueled by a rise in post-COVID pulmonary complications and increased awareness around interstitial lung disease (ILD) and pulmonary fibrosis diagnosis.

• By End User

On the basis of end user, the pulmonary function testing market is segmented into hospitals, specialty clinics, diagnostic laboratories, home care settings, and others. The hospitals segment accounted for the largest market revenue share of 48.9% in 2024, owing to their comprehensive diagnostic infrastructure, presence of trained professionals, and increasing patient footfall for respiratory evaluations. Government and private hospital investments in non-invasive respiratory diagnostic equipment are further contributing to segment growth.

The home care settings segment is projected to grow at the fastest rate of 19.6% from 2025 to 2032, driven by the rising trend of remote health monitoring, availability of portable spirometry devices, and the growing preference among patients—particularly elderly and chronic respiratory sufferers—for at-home diagnostic convenience and teleconsultation compatibility.

Asia-Pacific Pulmonary Function Testing Market Regional Analysis

• China dominated the Asia-Pacific pulmonary function testing market with the largest revenue share of 39.3% in 2024, supported by large-scale investments in healthcare infrastructure, high incidence of respiratory diseases, and a strong public health focus on chronic disease screening
• The country’s rapid urbanization, high pollution levels, and growing elderly population contribute to the increasing demand for pulmonary diagnostics, with hospitals and community health centers widely adopting spirometry and other lung function testing tools
• This strong market position is further supported by national healthcare reforms, public health initiatives such as Healthy China 2030, and expanding access to portable testing technologies, making China a key driver of growth in the region’s pulmonary function testing market

The China Pulmonary Function Testing Market Insight

The China pulmonary function testing market captured the largest revenue share in Asia-Pacific in 2024, driven by high rates of COPD and asthma, extensive healthcare reforms, and strong government emphasis on chronic disease prevention. Initiatives such as Healthy China 2030 are promoting early respiratory screening, while hospitals and public health centers increasingly deploy spirometry and body plethysmography systems. China's manufacturing strength and digital health ecosystem are also supporting cost-effective device availability and large-scale deployment across urban and rural regions.

India Pulmonary Function Testing Market Insight

The India pulmonary function testing market is anticipated to grow at a robust CAGR during the forecast period, fueled by rising urban air pollution, increasing tobacco usage, and strong government investment in diagnostic infrastructure. The adoption of portable pulmonary function devices in mobile health clinics and community health programs is expanding access in semi-urban and rural areas. In addition, the growing burden of respiratory illnesses such as asthma and tuberculosis, along with the push for affordable healthcare solutions, is propelling market growth in both public and private sectors.

Japan Pulmonary Function Testing Market Insight

The Japan pulmonary function testing market is gaining traction due to the country’s aging population, advanced healthcare system, and strong focus on chronic disease monitoring. Pulmonary diagnostics are widely adopted in routine checkups and long-term care centers, particularly for elderly patients. Japan's preference for technologically advanced and accurate testing solutions is driving demand for high-end spirometry and integrated diagnostic systems. In addition, innovation in portable and digital health tools is supporting the expansion of respiratory diagnostics beyond traditional hospital settings.

South Korea Pulmonary Function Testing Market Insight

The South Korea pulmonary function testing market is expanding steadily, driven by a technologically advanced healthcare system and growing emphasis on preventive care. Rising awareness of air pollution-related health risks and increasing incidence of asthma and bronchitis are propelling demand for pulmonary testing across hospitals and specialty clinics. The government’s proactive stance on digital health integration and the widespread use of EMR systems further support the adoption of advanced diagnostic tools. South Korea’s aging population and strong public health programs are also contributing to the growing need for accurate and routine lung function assessments.

Asia-Pacific Pulmonary Function Testing Market Share

The Asia-Pacific pulmonary function testing industry is primarily led by well-established companies, including:

• ndd Medical Technologies, Inc. (Switzerland)
• Schiller AG (Switzerland)
• MGC Diagnostics Corporation (U.S.)
• Vyaire Medical, Inc. (U.S.)
• COSMED Srl (Italy)
• CHEST M.I., Inc. (Japan)
• FUKUDA DENSHI CO., LTD. (Japan)
• Konica Minolta, Inc. (Japan)
• Nihon Kohden Corporation (Japan)
• Koninklijke Philips N.V. (Netherlands)
• Vitalograph Ltd. (U.K.)
• SDI Diagnostics, Inc. (U.S.)
• Spirobank by MIR Srl (Italy)
• Thorasys Thoracic Medical Systems Inc. (Canada)
• AEI Technologies, Inc. (U.S.)
• Jiangsu Yuyue Medical Instruments Co., Ltd. (China)
• Beijing Aeonmed Co., Ltd. (China)
• Nanjing Chenwei Medical Equipment Co., Ltd. (China)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)

What are the Recent Developments in Asia-Pacific Pulmonary Function Testing Market?

• In April 2023, NDD Medical Technologies, a global leader in pulmonary function testing devices, expanded its presence in the Asia-Pacific region by launching its next-generation portable spirometry system in India and Southeast Asia. The device, designed for primary care and community health settings, offers real-time results, Bluetooth connectivity, and cloud integration. This move reflects NDD’s commitment to improving early respiratory disease detection and enhancing accessibility to diagnostic tools in underserved markets
• In March 2023, Vitalograph, a renowned respiratory diagnostics company, announced the establishment of a new distribution and service center in Malaysia to support its growing customer base across Southeast Asia. The facility aims to provide localized support, faster delivery of pulmonary testing equipment, and training resources for healthcare professionals. This strategic investment underscores the company’s effort to strengthen its footprint and meet rising demand in the Asia-Pacific respiratory diagnostics market
• In March 2023, KoKo, LLC partnered with a leading Japanese healthcare distributor to bring its range of pulmonary function analyzers and spirometry solutions to hospitals and clinics across Japan. The collaboration focuses on addressing the country's aging population and increasing need for accurate respiratory testing. With an emphasis on digital integration and compact device designs, this partnership highlights KoKo’s strategy to adapt its offerings to regional market needs and clinical workflows
• In February 2023, CHEST M.I., Inc., a Japanese medical device manufacturer specializing in respiratory diagnostics, launched its next-gen spirometer with AI-enabled analysis software. Designed for both clinical and home-care environments, the device features automatic interpretation support and cloud data sharing. This advancement reflects the growing trend of AI integration in pulmonary diagnostics, aimed at improving accuracy and enabling remote consultations
• In January 2023, SDI Diagnostics expanded its regional distribution channels by partnering with healthcare providers across Australia and New Zealand. The initiative includes the rollout of new mobile pulmonary testing kits tailored for occupational health and remote respiratory screening. This development reinforces the company’s focus on portability, ease of use, and supporting regional healthcare systems in improving respiratory disease management and early detection efforts

SKU-72775